Discover investment opportunities in Digital Biology Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Digital Biology Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Digital Biology Stocks using our Smart AI Filter.
8 stocks found for "Digital Biology Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.77 | ±71.4% | -18.6 | 0.00% | |||
0.37 | ±22.9% | 21.1 | 0.52% | |||
1.19 | ±53.7% | -156.9 | 0.00% | |||
1.19 | ±37.2% | 15.3 | 0.76% | |||
1.82 | ±67.7% | -15.1 | 0.00% | |||
0.89 | ±41.9% | 22.8 | 0.00% | |||
1.65 | ±68.2% | -10.2 | 0.00% | |||
1.59 | ±71.9% | 33.2 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How has CRISPR technology influenced the growth potential of companies like CRSP and EDIT?
A: CRISPR technology, utilized by CRSP and EDIT, is considered revolutionary for gene editing applications. It offers potential for breakthroughs in disease treatment, thus driving investor interest and market potential. The technology's rapid advancement is appealing for long-term growth investors focused on innovative biotech solutions.
Q: What are the primary risks associated with investing in ILMN, a key player in digital biology?
A: ILMN, a leader in genomic sequencing, faces risks such as regulatory hurdles, high R&D costs, and competition from emerging startups. Additionally, rapid technological advancements may render existing tools obsolete, impacting ILMN's competitive position and investor confidence.
Q: Why might NVTA attract investors interested in personalized medicine?
A: NVTA specializes in genetic testing for personalized medicine, which is pivotal for tailored healthcare solutions. This niche appeals to investors focused on technologically advanced healthcare models, emphasizing individualized patient care and long-term market adoption potential.
Q: How does PACB stand out in the growing field of DNA sequencing?
A: PACB is noted for its unique single-molecule, real-time DNA sequencing technology, offering high accuracy and extensive data output. This technological edge provides competitive advantage, attracting investors interested in cutting-edge solutions and advancements in genomic research.
Q: Do genome editing firms like BEAM and NTLA show potential for future profitability?
A: Genome editing firms BEAM and NTLA have yet to reach profitability, focusing heavily on R&D to advance gene-editing therapies. Historically, the potential for high-impact clinical breakthroughs may suggest upward financial trajectories once commercial products are developed.
Q: Can TWST appeal to environmentally conscious investors?
A: TWST’s synthetic biology platform, used in diverse fields like agriculture and sustainability, aligns with ESG values. It offers investors exposure to environmentally friendly applications, improving efficiency and reducing the ecological footprint of bio-production processes.
The heavy selling pressure might have exhausted for Twist Bioscience (TWST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read moreInvestors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Qiagen (QGEN) or Exact Sciences (EXAS). But which of these two stocks presents investors with the better value opportunity right now?
Read more